Poly (ADP-ribose) polymerase inhibitors: recent advances and future development

• Published in: Journal of clinical oncology Vol. 33; no. 12; pp. 1397 - 1406
• Main Authors: Scott, Clare L, Swisher, Elizabeth M, Kaufmann, Scott H
• Format: Journal Article
• Language: English
• Published: United States American Society of Clinical Oncology 20.04.2015
• Subjects: Animals; Biology of Neoplasia; Bon; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Enzyme Inhibitors - pharmacology; Enzyme Inhibitors - therapeutic use; Female; Humans; Neoplasms, Glandular and Epithelial - drug therapy; Neoplasms, Glandular and Epithelial - enzymology; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - enzymology; Poly(ADP-ribose) Polymerase Inhibitors

Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease. Consistent with preclinical studies, ovarian cancers and a number of other solid tumor types occurring in patients with delete...